Mirum Pharma holders approve 2026 director slate, pay

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

Key Figures

Key Terms

What did Mirum Pharmaceuticals (MIRM) stockholders vote on at the 2026 annual meeting?

How many Mirum Pharmaceuticals (MIRM) shares were entitled to vote at the 2026 meeting?

Which directors were elected at Mirum Pharmaceuticals’ 2026 annual meeting?

Was Mirum Pharmaceuticals’ auditor ratified for the 2026 fiscal year?

Did Mirum Pharmaceuticals (MIRM) stockholders approve executive compensation on an advisory basis?

What were the vote results for Mirum director Timothy Walbert’s election?

Mirum Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 15, 2026.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Mirum Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 15, 2026. As of the April 20, 2026 record date, 60,977,841 shares of common stock were outstanding and entitled to vote.

Stockholders elected three Class I directors—Lon Cardon, William Fairey, and Timothy Walbert—to serve until the 2029 annual meeting and until their successors are duly elected and qualified. Mirum’s stockholders also ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of the company’s named executive officers.

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Shares entitled to vote: 60,977,841 shares Votes for auditor ratification: 49,993,514 votes Votes for say-on-pay: 44,534,575 votes +3 more

6 metrics

Shares entitled to vote 60,977,841 shares Common stock outstanding as of April 20, 2026 record date

Votes for auditor ratification 49,993,514 votes Ernst & Young LLP as auditor for year ending December 31, 2026

Votes for say-on-pay 44,534,575 votes Advisory approval of named executive officer compensation

Votes for Lon Cardon 39,587,327 votes Election as Class I director

Votes for William Fairey 40,266,848 votes Election as Class I director

Votes for Timothy Walbert 32,329,718 votes Election as Class I director

Broker Non-Votes, independent registered public accounting firm, Advisory Vote on Executive Compensation, Audit Committee

4 terms

Broker Non-Votes financial

"Votes For | | Votes Withheld | | Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"Ernst & Young LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Advisory Vote on Executive Compensation financial

"Proposal 3. Advisory Vote on Executive Compensation"

A non-binding shareholder vote allowing investors to approve or reject the pay packages and compensation policies for a company’s top executives. It matters because the outcome tells the board whether owners are satisfied with executive pay and can prompt changes in policy or leadership much like a customer survey prompts a company to adjust its product — signaled approval can support management credibility, while rejection may increase scrutiny and affect investor confidence.

Audit Committee financial

"selection by the Audit Committee of the Company’s Board of Directors"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Stockholders voted on electing three Class I directors, ratifying Ernst & Young LLP as independent auditor for 2026, and approving an advisory resolution on executive compensation. All three proposals received sufficient support to pass at the meeting.

A total of 60,977,841 shares of Mirum Pharmaceuticals common stock were outstanding and entitled to vote as of April 20, 2026. This figure represents the voting base used to determine approval of all proposals presented at the annual meeting.

Stockholders elected Lon Cardon, William Fairey, and Timothy Walbert as Class I directors. Each director will serve until Mirum Pharmaceuticals’ 2029 annual meeting of stockholders, and until a successor is duly elected and qualified or earlier death, resignation, or removal.

Yes. Stockholders ratified the Audit Committee’s selection of Ernst & Young LLP as Mirum Pharmaceuticals’ independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 49,993,514 votes for, 5,674 against, and 30,192 abstentions.

Yes. Stockholders approved, on an advisory basis, the compensation of Mirum Pharmaceuticals’ named executive officers. The proposal received 44,534,575 votes for, 1,866,719 votes against, 13,247 abstentions, and 3,614,839 broker non-votes as reported in the meeting results.

For director Timothy Walbert, stockholders cast 32,329,718 votes for and 14,084,823 votes withheld, with 3,614,839 broker non-votes. Despite the higher number of withheld votes relative to other nominees, he was elected as a Class I director through the 2029 annual meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/18/2026 - 04:05 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2026

Mirum Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-38981	83-1281555
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

989 East Hillsdale Boulevard

Suite 300

Foster City, California

94404

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (650) 667-4085

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	MIRM	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 15, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 20, 2026, the record date for the Annual Meeting, 60,977,841 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

Proposal 1. Election of Directors

The Company’s stockholders elected the three persons listed below as Class I directors, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:


	Votes For	Votes Withheld	Broker Non-Votes
Lon Cardon, Ph.D., FMedSci	39,587,327	6,827,214	3,614,839
William Fairey	40,266,848	6,147,693	3,614,839
Timothy Walbert	32,329,718	14,084,823	3,614,839

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:


Votes For	Votes Against	Abstentions
49,993,514	5,674	30,192

Proposal 3. Advisory Vote on Executive Compensation

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement for the Annual Meeting. The final voting results are as follows:


Votes For	Votes Against	Abstentions	Broker Non-Votes
44,534,575	1,866,719	13,247	3,614,839

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

Mirum Pharmaceuticals, Inc.

Date: June 18, 2026

/s/ Christopher Peetz

Christopher Peetz

Chief Executive Officer

3 documents